這是一項多中心、開放標籤、分層、隨機研究，旨在評估 durvalumab 或 tremelimumab 單藥治療，或 durvalumab 聯合 tremelimumab 或 bevacizumab 用於晚期肝細胞癌的安全性、耐受性、抗腫瘤活性、藥物動力學、藥效學及免疫原性。

適應症：Hepatocellular Carcinoma

收案條件

Male or female participants
years and older (Japan-20 years and older)
Confirmed hepatocellular carcinoma (HCC) based on histopathological findings from tumor tissues. Advanced HCC with diagnosis confirmed pathologically or with noninvasive methods.
Immunotherapy-naïve
Have either progressed on, are intolerant to, or refused treatment with sorafenib or another approved TKI. For arm 5 only: Have not received any prior systemic therapy for HCC.

Prior exposure to immune-mediated therapy
Hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy
Gastrointestinal bleeding (eg, esophageal varices or ulcer bleeding) within 12 months
Ascites requiring non-pharmacologic intervention (eg, paracentesis) to maintain symptomatic control, within 6 months prior to the first scheduled dose.
Main portal vein thrombosis (Vp4) as documented on imaging
Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment
Active or prior documented autoimmune or inflammatory disease with some exceptions
Current or prior use of immunosuppressive medication within 14 days with some exceptions

收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。

Durvalumab 或 Tremelimumab 單藥治療，或 Durvalumab 聯合 Tremelimumab 或 Bevacizumab 用於晚期肝細胞癌的研究